Sometimes an unconventional device company needs an unconventional investor. That's true of mNemoscience, which was launched from the MIT lab of Robert Langer to develop materials technology that combines the shape memory properties commonly associated with nitinol and biodegradability. The combined properties could represent important advances in a number of device areas, and the company is starting in coronary stents and sutures. But, not surprisingly, mNemoscience has taken a long time in its technology development efforts and has had to find just the right financing model. What mNemoscience had to offer its unconventional investor provides an instructive tale to medtech executives and scientists everywhere.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?